Seprase (FAP)-Targeted Theranostic Radiopharmaceuticals Development
Seprase (FAP)-targeted theranostic radiopharmaceuticals are taking a frontier role in innovative cancer treatment solutions. Take advantage of extensive expression of seprase (FAP) on cancer-associated fibroblasts, which allows imaging and treatment to be combined. Alfa Cytology understands the peculiar troubles that arise in this field and, therefore, offers completely integrated development services for seprase (FAP)-targeted theranostic therapies in accelerated adoption of sophisticated solutions.
Introduction to Seprase (FAP)-Targeted Theranostic Radiopharmaceuticals
The development of integrated therapeutics targeting seprase (FAP) has developed into a key subject in cancer research. seprase (FAP)-targeted theranostic radiopharmaceuticals present an original class of therapeutic agents developed specifically to hit seprase (FAP), a serine protease with a high expression in several types of fibroblasts associated with epithelial tumors. By binding to seprase (FAP), these agents lead to thorough diagnosis and treatment of the tumor and thus have drawn considerable interest in this field.
Fig. 1 Development of fibroblast activation protein-a radiopharmaceuticals: Recent advances and perspectives. (Yu, Z., et al. 2024)
Mechanisms of Seprase (FAP)-Targeted Theranostic Radiopharmaceuticals
Seprase (FAP)-targeted theranostic radiopharmaceuticals represent a new class of agents acting as diagnostic and therapeutic agents, which means that together these can be used for the imaging and treatment of tumors.
Diagnosis
These include seprase (FAP) inhibitors radiolabelled with isotopes for targeting seprase (FAP) in the tumor microenvironment. seprase (FAP) inhibitors chemically conjugated with radioactive isotopes and imaged via techniques like positron emission tomography (PET) or single-photon emission computed tomography (SPECT) help in utilizing diagnostic imaging with very high precision for the tumor.
Therapy
The therapeutic capability of seprase (FAP)-targeted radiopharmaceuticals primarily depends on their radioactive component. The isotope being released gives off damaging radiation upon binding with tumor cells, resulting in DNA damage and cell death. This provides a significant targeted accumulation of agents within the tumor microenvironment to enhance therapeutic performance.
Development of Seprase (FAP)-Targeted Theranostic Radiopharmaceuticals
The following are theranostic radiopharmaceuticals drug development that target seprase (FAP), including but not limited to:
| Name | Indication | NCT Number | Phase |
|---|---|---|---|
| [68Ga/177Lu] Ga/Lu-DOTA-NI-FAPI-04 | Solid Tumors | NA | Preclinical |
| TLX591 | Prostate Cancer | NCT06520345 | Phase III |
Disclaimer: Alfa Cytology focuses on providing preclinical research service. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
Our Services
At Alfa Cytology, our team comprises experienced scientists that together work towards advancing the field of seprase (FAP)-targeted theranostic radiopharmaceuticals. Our focus lies in developing novel therapy that integrates diagnostic capability, combined with a thorough understanding of seprase (FAP) biology and radiopharmaceutical chemistry. Equipped with state-of-the-art laboratories and a collaborative team of multidisciplinary experts, we have built a complete array of services to help smoothen and speed up the process of drug development.
- Target Validation: Analyze expression levels of seprase (FAP) in different tumors and study its biological functions.
- Basic Research: Conduct cell experiments, construct animal models, and study the mechanisms of drug action.
Drug Design and Synthesis
- Drug Design: Design and develop small-molecule inhibitors, peptides, antibodies, and other anti-seprase (FAP) drugs and provide expertise.
- Drug Synthesis: Offer comprehensive synthesis services for theranostic agents.
- High-Throughput Screening: Using high-throughput platforms to identify candidate small drug-like molecules and bioactive compounds.
- Structural Optimization: Improve the chemical structure, pharmacological, and toxicological properties of the drugs.
- In Vitro Assay: Testing the cellular uptake and cytotoxicity of the drugs.
- In Vivo Assay: Assessment of biodistribution, pharmacokinetics, and pharmacodynamics of the drug candidate in animal models.
Alfa Cytology provides a complete variety of development services for seprase (FAP)-targeted theranostic radiopharmaceuticals, from original design and synthesis with high purity to complete preclinical evaluation. We're here to help you find the best drug candidates for your needs or feel free to contact us for further discussions on possible collaborations.
Reference
- Yu, Z., et al. Development of fibroblast activation protein-α radiopharmaceuticals: Recent advances and perspectives. European journal of medicinal chemistry. 2024, 277: 116787.
For research use only.